drugset / Trial / NCT02687542
Efficacy, Safety and Tolerability of PF-06649751 in Parkinson's Disease Patients With Motor Fluctuations
RandomizedTriple-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy, safety and tolerability of PF-06649751 in Parkinson's disease patients who experience motor-fluctuations.
Timeline
- Start
- 2016-03-03
- Primary completion
- 2017-11-10
- Completion
- 2017-11-10
Outcome
Missed primary endpoint
Stopped: “Terminated 25Sep17 due to insufficient efficacy. Not due to safety reasons.”
registry analysis (other test); Placebo vs PF-06649751 15 mg QD; p = 0.5776; Bayesian Dose Reponse Estimate -0.693 (90% CI -1.713 to 0.304); NCT02687542 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tavapadon | Small molecule | 1 mg | — |
| Subject | Tavapadon | Small molecule | 3 mg | — |
| Subject | Tavapadon | Small molecule | 7 mg | — |
| Subject | Tavapadon | Small molecule | 15 mg | — |